Half-year report · Q2
2590.TEDINET S100UB7G
Period2024-01-21 → 2024-07-20
Filed2024-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥117.6bn | 2024-01-21 → 2024-07-20 | Cons. | Net sales |
| Revenue | ¥213.4bn | 2023-01-21 → 2024-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥101.7bn | 2023-01-21 → 2023-07-20 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2024-01-21 → 2024-07-20 | Cons. | Operating income |
| Operating income | ¥2.5bn | 2023-01-21 → 2023-07-20 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2024-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-01-21 → 2024-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2023-01-21 → 2023-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥6.5bn | 2024-01-21 → 2024-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2023-01-21 → 2023-07-20 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.9bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.4bn | 2023-01-21 → 2024-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2023-01-21 → 2023-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.7bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2023-01-21 → 2023-07-20 | Cons. | Profit loss |
| Total assets | ¥199.3bn | at 2024-07-20 | Cons. | Assets |
| Total assets | ¥177.6bn | at 2024-01-20 | Cons. | Assets |
| Total assets | ¥182.1bn | at 2023-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.2bn | at 2024-07-20 | Cons. | Liabilities |
| Total liabilities | ¥86.1bn | at 2024-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥94.2bn | at 2024-07-20 | Cons. | Net assets |
| Net assets / equity | ¥91.5bn | at 2024-01-20 | Cons. | Net assets |
| Net assets / equity | ¥87.8bn | at 2023-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥36.5bn | at 2024-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥32.4bn | at 2024-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥36.3bn | at 2024-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.0bn | at 2023-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.2bn | at 2023-01-20d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥5.5bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.2bn | 2023-01-21 → 2024-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.7bn | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.1bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2023-01-21 → 2024-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.8bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2023-01-21 → 2024-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥50m | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥155.7 | 2024-01-21 → 2024-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.77 | 2023-01-21 → 2024-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.64 | 2023-01-21 → 2023-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.4% | at 2024-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2024-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2023-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2024-07-20 | −¥674m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥17m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥238m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥295m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥899m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥2.3bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥6.9bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥6.7bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥146m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥324m |
| —segment total | revenue | 2024-01-21 → 2024-07-20 | ¥117.7bn |
| —segment total | revenue external | 2024-01-21 → 2024-07-20 | ¥117.6bn |
| —segment total | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥167m |
| —segment total | segment profit | 2024-01-21 → 2024-07-20 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2023-01-21 → 2023-07-20 | −¥204m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-21 → 2023-07-20 | −¥204m |
| Reconciling Itemsreconciling | segment profit | 2023-01-21 → 2023-07-20 | −¥502m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥74.3bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥74.2bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥19m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥1.8bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2023-01-21 → 2023-07-20 | −¥296m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥776m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥10.5bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥10.5bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥462m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥6.4bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥6.2bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥180m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥239m |
| —segment total | revenue | 2023-01-21 → 2023-07-20 | ¥102.0bn |
| —segment total | revenue external | 2023-01-21 → 2023-07-20 | ¥101.7bn |
| —segment total | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥204m |
| —segment total | segment profit | 2023-01-21 → 2023-07-20 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 557
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 101950000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -204000000 | JPY |
| Net sales | Prior1YTDDuration | 101746000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 1847000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 462000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 239000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 776000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -296000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 3029000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -502000000 | JPY |
| Operating income | Prior1YTDDuration | 2527000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 72992000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 26757000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6726000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 11102000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 117578000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 117578000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 17000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 146000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 167000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -167000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 73009000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 26757000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6872000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 11106000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 117745000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -167000000 | JPY |
| Net sales | CurrentYTDDuration | 117578000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | -238000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 2303000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 324000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 899000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -295000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 2993000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -674000000 | JPY |
| Operating income | CurrentYTDDuration | 2319000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-09-03 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第50期中（自 2024年1月21日 至 2024年7月20日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ダイドーグループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | DyDo GROUP HOLDINGS,INC. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |